Multi-sample SNP calling circa 1994

Last November, when news of Fred Sanger‘s death was making its way around scientific circles, so too were many images of Sanger DNA sequencing reactions visualized as autoradiograms. These images brought back memories of a style of Sanger sequencing gel that I first saw in an undergraduate class on population genetics taught by Charles (“Chip”) Aquadro at Cornell University in the autumn of 1994, which left a deep impression on me. My personal photograph 51, if you will.

At the time, I was on course to be a high-school biology teacher, a plan that was scuppered by being introduced to the then-emerging field of molecular population genetics covered in Aquadro’s class. I distinctly remember Aquadro putting up a transparency on the overhead showing an image of a Sanger gel where each of the four bases were run in sets that included each individual in the sample, allowing single nucleotide polymorphisms (“SNPs”) to be easily identified by eye. This image made an extremely strong impression on me, transforming the abstract A and a alleles typically discussed in population genetics into concrete molecular entities. Together with the rest of the material in Aquadro’s class, this image convinced me to pursue a career in evolutionary genetics.

I emailed Aquadro around that time last year to see if he had such an image digitized, and he said he’d try to dig one out. A few weeks ago he sent me the following image, which shows the state-of-the-art in multi-sample SNP calling circa 1994:

SangerSequencingGel-RosyDmel-Aquadro

Multi-sample Sanger sequencing gel of a fragment of the Drosophila melanogaster rosy (Xdh) gene (credit: Charles Aquadro). The first four lanes represent the four bases of the “reference” sequence, followed by four sets of lanes (one for each base) containing sequencing reactions for each individual in the sample. Notice how when a band is missing from a set for one individual, it is present in a different set for that same individual. This format allowed the position and identity of variable sites in a sample to be identified quickly, without having to read off the complete sequence for each individual.

For those of us who now perform multi-sample SNP calling at the whole-genome scale using something like a Illumina->BWA->SAMtools pipeline, it is sometimes hard to comprehend how far things have progressed technologically in the last 20 years.

Perhaps equally dramatic are the changes in the larger social and scientific value placed on the use of sequence analysis and the identification of variation in natural populations. At that time, the Aquadro lab was referred to in a friendly, if somewhat disparaging, way as the “Sequence and Think Lab” by others in the department (because “all they do in that lab is sequence and think”). As the identification of natural molecular variation in humans quickly becomes the basis for personalized medicine, and as next-generation sequencing is incorporated into more basic molecular biological techniques, it is impressive to see how quickly the “sequence and think” model has moved from a peripheral to a central role in modern biology.

 

Advertisements

On the 30th Anniversary of DNA Sequencing in Population Genetics

30 years ago today, the “struggle to measure genetic variation” in natural populations was finally won. In a paper entitled “Nucleotide polymorphism at the alcohol dehydrogenase locus of Drosophila melanogaster” (published on 4 Aug 1983), Martin Kreitman reported the first effort to use DNA sequencing to study genetic variation at the ultimate level of resolution possible. Kreitman (1983) was instantly recognized as a major advance and became a textbook example in population genetics by the end of the 1980s. John Gillespie refers to this paper as “a milestone in evolutionary genetics“. Jeff Powell in his brief history of molecular population genetics goes so far as to say “It would be difficult to overestimate the importance of this paper”.

Arguably, the importance of Kreitman (1983) is greater now than ever, in that it provides both the technical and conceptual foundations for the modern gold rush in population genomics, including important global initiatives such as the 1000 Genomes Project. However, I suspect this paper is less well know to the increasing number of researchers who have come to studying molecular variation from routes other than through a training in population genetics. For those not familiar with this landmark paper, it is worth taking the time to read it or Nathan Pearson‘s excellent summary over on Genomena.

As with other landmark scientific efforts, I am intrigued by how such projects and papers come together. Powell’s “brief history” describes how Kreitman arrived at using DNA to study variation in Adh, including some direct quotes from Kreitman (p. 145). However, this account leaves out an interesting story about the publication of this paper that I had heard bits and pieces of over time. Hard as it may be to imagine in today’s post-genomic sequence-everything world, using DNA sequencing to study genetic variation in natural populations was not immediately recognized as being of fundamental importance, at least by the editors of Nature where it was ultimately published.

To better understand the events of the publication of this work, I recently asked Richard Lewontin, Kreitman’s PhD supervisor, to provide his recollections on this project and the paper. Here is what he had to say by email (12 July 2013):

Dear Casey Bergman

I am delighted that you are commemorating Marty’s 1983 paper that changed the whole face of experimental population genetics. The story of the paper is as follows.

It was always the policy in our lab group that graduate students invented their own theses. My view was (and still is) that someone who cannot come up with an idea for a research program and a plan for carrying it out should not be a graduate student. Marty is a wonderful example of what a graduate student can do without being told what to do by his or her professor. Marty came to us from a zoology background and one day not very long after he became a member of the group he came to me and asked how I would feel about his investigating the genetic variation in Drosophila populations by looking at DNA sequence variation rather than the usual molecular method of looking at proteins which then occupied our lab. My sole contribution to Marty’s proposal was to say “It sounds like a great idea.”  I had never thought of the idea before but it became immediately obvious to me that it was a marvelous idea.  So Marty went over on his own initiative, to Wally Gilbert’s lab and learned all the methodology from George Church who was then in the Gilbert lab.

After Marty’s work was finished and he was to get his degree, he wrote a paper based on his thesis and, with my encouragement, sent the paper to Nature. He offered to make me a co-author, but I refused on long-standing principle. Since the idea and the work were entirely his, he was the sole author, a policy that was general in our group. I had no doubt that it was the most important work done in experimental population genetics  in many years and Nature was an obvious choice for this pathbreaking work.

The paper was soon returned by the Editor saying that they were not interested because they already had so many papers that gave the DNA sequence of various genes that they really did not want yet another one! Obviously they missed the point. My immediate reaction was to have Marty send the paper to a leading influential British Drosophila geneticist who would obviously understand its importance, asking him to retransmit the paper to Nature with his recommendation. He did so and the Editor of Nature then accepted it for publication. The rest is history.

Our own lab very quickly converted from protein electrophoresis to DNA sequencing, and I spent a lot of time using and updating the computer interface with the gel reading process, starting from  Marty’s original programs for reading gels and outputting sequences. We never went back to protein electrophoresis. While protein gel electrophoresis certainly revolutionized population genetics, Marty’s introduction of DNA sequencing as the method for evolutionary genetic investigation of population genetic issues was a much more powerful one and made possible the testing of a  variety of evolutionary questions for which protein gel electrophoresis was inadequate. Marty deserves to be considered as one of the major developers of evolutionary and population genetics studies.

Yours ,

Dick Lewontin

Some may argue that Kreitman (1983) did not reveal all forms of genetic variation at the molecular level (e.g. large-scale structural variants) and therefore does not truly represent the “end” of the struggle to measure variation. What is clear, however, is that Kreitman (1983) does indeed represent the beginning of the “struggle to interpret genetic variation” at the fundamental genetic level, a struggle that may ultimately take longer then measuring variation itself. According to Maynard Olson interpreting (human) genomic variation will be a multi-generational effort “like building the European cathedrals“. 30 years in, Olson’s assessment is proving to be remarkably accurate. Here’s to Kreitman (1983) for laying the first stone!

Related Posts:

Directed Genome Sequencing: the Key to Deciphering the Fabric of Life in 1993

Seeing the #AAASmtg hashtag flowing on my twitter stream over the last few days reminded my that my former post-doc advisor Sue Celniker must be enjoying her well-deserved election to the American Association for the Advancement of Science (AAAS). Sue has made a number of major contributions to Drosophila genomics, and I personally owe her for the chance to spend my journeyman years with her and so many other talented people in the Berkeley Drosophila Genome Project. I even would go so far as to say that it was Sue’s 1995 paper with Ed Lewis on the “Complete sequence of the bithorax complex of Drosophila” that first got me interested in “genomics.” I remember being completely in awe of the Genbank accession from this paper which was over 300,000 bp long! Man, this had to be the future. (In fact the accession number for the BX-C region, U31961, is etched in my brain like some telephone numbers from my childhood.) By the time I arrived at BDGP in 2001, the sequencing of the BX-C was already ancient history, as was the directed sequencing strategy used for this project.  These rapid changes made discovery of a set of discarded propaganda posters collecting dust in Reed George’s office that were made at the time (circa 1993) extolling the virtues of “Directed Genome Sequencing” as the key to “Deciphering the Fabric of Life” all the more poignant. I dug a photo I took of one of these posters today to commemerate the recognition of this pioneering effort (below). Here’s to a bygone era, and hats off to pioneers like Sue who paved the road for the rest of us in (Drosophila) genomics!

Directed-genome-sequencing

From Electron to Retrotransposon: “-on” the Origin of a Common Suffix in Molecular Biology

Over the last year or so, I have become increasingly interested in understanding the origin of major concepts in genetics and molecular biology. This is driven by several motivating factors, primarily to cure my ignorance/satisfy my curiosity but also to be able to answer student queries more authoritatively and unearth unsolved questions in biology. One of the more interesting stories I have stumbled across relates to why so many terms in molecular biology (e.g. codon, replicon, exon, intron, transposon, etc.) end with the suffix “-on”? While nowhere as pervasive the “-ome” suffix that has contaminated biological parlance of late,  the suffix “-on” has clearly left its mark in some of the most frequently used terms the lexicon of molecular biology.

According to Brenner (1996) [1], the common use of the suffix “-on” in molecular biological terms can be traced to Seymour Benzer’s dissection of the fine structure of the rII locus in bacteriophage T4, which overturned the classical idea that a gene is an indivisible unit:

To mark this new view of the gene, Seymour invented new terms for the now different units of mutation, recombination and function. As he was a physicist, he modelled his terms on those of physics and just as electrons, protons and neutrons replaced the once indivisible atom, so genes came to be composed of mutons, recons and cistrons. The the unit of function, the cistron was based on the cis–trans complementation test, of which only the trans part is usually done…Of these terms, only cistron came to be widely used. It is conjectured that the other two, the muton and the recon, disappeared because Seymour failed to follow the first rule for inventing new words, which is to check what they may mean in other languages…Seymour’s pioneering invention of units was followed by a spate of other new names not all of which will survive. One that seems to have taken root is codon, which I invented in 1957; and the terms intron and exon, coined by Walter Gilbert, are certain to survive as well. Operon is moot; it is still frequently used in prokaryotic genetics but as the weight of research shifts to eukaryotes, which do not have such units of regulation, it may be lost. Replicon, invented by Francis Jacob and myself in 1962, seems also to have survived, despite the fact that we paid insufficient attention to how it sounded in other languages.

Thus, the fact that many molecular biological terms end in “-on” (initiated by Benzer) owes its origin to patterns of nomenclature in chemistry/nuclear physics (which itself began with Stoney’s proposal of the term electron in 1894) and the desire to identify “fundamental units” of biological structure and function.

While Brenner’s commentary provides a crucial first-hand account to understand the origin of these terms, it does not provide any primary references concerning the coining of these terms. So I’ve spent some time digging out the original usage for a number of more common molecular biology “-ons”, which I thought many be of use or interest to others.

The terms reconmuton and cistron were defined by Benzer (1957) [2] as follows:

  • Recon: “The unit of recombination will be defined as the smallest element in the one-dimensional array that is interchangeable (but not divisible) by genetic recombination. One such element will be referred to as a “recon.””
  • Muton: “The unit of mutation, the “muton” will be defined as the smallest element that, when altered, can give rise to a mutant form of the organism.”
  • Cistron: “A unit of function can be defined genetically, independent of biochemical information, by means of the elegant cistrans comparison devised by [Ed] Lewis…Such a map segment, corresponding to a function which is unitary as defined by the cistrans test applied to the heterocaryon, will be defined as a cistron.”

I have not been able to find a definitive first reference that defines the term codon the fundamental unit of the genetic code. According to Brenner (1996) [1] and US National Library of Medicine’s Profiles in Science webpage on Marshall Nirenberg [2], the term codon was introduced by Brenner in 1957 “to describe the fundamental units engaged in protein synthesis, even though the units had yet to be fully determined. Francis Crick popularized the term in 1959. After 1962, Nirenberg began to use “codon” to characterize the three-letter RNA code words” [3].

The term operon was introduced by Jacob et al. (1960) [4] and defined as follows (italics theirs):

  • Operon: “Celle-ci comprendrait des unités d’expression coordonée (opérons) constituées par un opérateur et le group de gènes de structure coodoneés par lui.”

The term replicon was introduced by Jacob and Brenner (1963) [4] and defined as follows (italics theirs):

  • Replicon: “Il est donc clair qu’un chromosome (de bactérie ou de phage) ou un épisome constitue une unité de réplication indépendante ou réplicon, dont la reproduction est régie par la présence et l’activité de certain déterminants qu’il porte. Les caractères des réplicons exigent qu’ils déterminent des systèmes spécifique gouvernant leur propre réplication.”

Near and dear to my heart is the term transposon, which was first introduced by Hedges and Jacob (1974) [7] (italics theirs):

  • Transposon: “We designate DNA sequences with transposition potential as transposons (units of transposition)”

The very commonly used terms intron and exon were defined by Gilbert (1978) [6] as follows:

  • Intron & Exon: “The notion of the cistron, the genetic unit of function that one thought to correspond to a polypeptide chain, must be replaced by that of a transcription unit containing regions which will be lost from the mature messenger – which I suggest we call introns (for intragenic regions) – alternating with regions which will be expressed – exons.”

And finally, Boeke et al. (1985) [8] defined the term retrotransposon in the following passage (italics theirs):

  • Retrotransposon: “These observations, together with the finding that introns are spliced out of the Ty upon transposition, suggest that reverse transcription is a step in the transposition of Ty elements…We therefore propose the term retrotransposon  for Ty and related elements.”

So there you have it, from electron to retrotransposon in just a few steps. I’ve left out some lesser used terms with this suffix for the moment (e.g. regulon, stimulon, modulon), so as not to let this post go -on and -on. If anyone has any major terms to add here or corrections to my reading of the tea leaves, please let me know in the comments below.

References:
[1] Brenner, S. (1995) “Loose end: Molecular biology by numbers… one.” Current Biology 5(8): 964.
[2] Benzer, S. (1957) “The Elementary Units of Heredity.” in Symposium on the Chemical Basis of Heredity p. 70–93.  Johns Hopkins University Press
[4] Jacob, F., et al. (1960) “L’opéron: groupe de gènes à expression coordonnée par un opérateur.” C.R. Acad. Sci. Paris 250: 1727-1729.
[5] Jacob, F., and S. Brenner. (1963) “Sur la regulation de la synthese du DNA chez les bacteries: l’hypothese du replicon.” C. R. Acad. Sci 246: 298-300.
[6] Gilbert, W. (1978) “Why genes in pieces?.” Nature 271(5645): 501.
[7] Hedges, R. W., and A. E. Jacob. (1974) “Transposition of ampicillin resistance from RP4 to other replicons.” Molecular and General Genetics MGG 132(1): 31-40.
[8] Boeke, J.D., et al. (1985) “Ty elements transpose through an RNA intermediate.” Cell 40(3): 491.
Credits:
Jim Shapiro (University of Chicago) gave very helpful pointers to possible places where the term “transposon” might have originally have been introduced.

On The Neutral Sequence Fallacy

ResearchBlogging.org

Beginning in the late 1960s, Motoo Kimura overturned over a century of “pan-selectionist” thinking in evolutionary biology by proposing what has come to be called The Neutral Theory of Molecular Evolution. The Neutral Theory in its basic form states that the dynamics of the majority of changes observed at the molecular level are governed by the force of Genetic Drift, rather than Darwinian (i.e. Positive) Natural Selection. As with all paradigm shifts in Science, there was much of controversy over the Neutral Theory in its early years, but nevertheless the Neutral Theory has firmly established itself as the null hypothesis for studies of evolution at the molecular level since the mid-1980s.

Despite its widespread adoption, over the last ten years or so there has been a worrying increase in abuse of terminology concerning the Neutral Theory, which I will collectively term here the “Neutral Sequence Fallacy” (inspired by T. Ryan Gregory’s Platypus Fallacy). The Neutral Sequence Fallacy arises when the distinct concepts of functional constraint and selective neutrality are conflated, leading to the mistaken description of functionally unconstrained sequences as being “Neutral”. The Fallacy, in short, is to assign the term Neutral to a particular biomolecular sequence.

The Neutral Sequence Fallacy now routinely causes problems in the fields of evolutionary and genome biology, both in terms of generating conceptual muddles as well as shifting the goalposts needed to reject the null model of sequence evolution. I have intended to write about this problem for years in order to put a halt to this growing abuse of Neutral terminology, but unfortunately never found the time. However, this issue has unfortunately reared its head more strongly in the last few days with new forms of the Neutral Sequence Fallacy arising in the context of discussions about the ENCODE project, motivating a rough version of this critique to finally see the light of day. Here I will try to sketch out the origins of the Neutral Sequence Fallacy, in its original pre-genomic form that was debunked by Kimura while he was alive, and in its modern post-genomic form that has proliferated unchecked since the early comparative genomic era.

The Neutral Sequence Fallacy draws on several misconceptions about the Neutral Theory, and begins with the abbreviation of the theory’s name from its full form (The Neutral Mutation – Random Drift Hypothesis) to its colloquial form (The Neutral Theory). This abbreviation de-emphasizes that the concept of selective neutrality applies to mutations (i.e. variants, alleles), not biomolecular sequences (i.e. regions of the genome, proteins). Simply put, only variants of a sequence can be neutral or non-neutral, not sequences themselves.

The key misconception that permits the Neutral Sequence Fallacy to flourish is the incorrect notion that if a sequence is neutrally evolving, it implies a lack of functional constraint operating on that sequence, and vice versa. Other ways to state this misconception are: “a sequence is Neutral if it is under no selective constraint” or conversely “selective constraint rejects Neutrality”. This misconception arose originally in the 1970s, shortly after the proposal of The Neutral Theory when many researchers were first coming to terms with what the theory meant. This misconception became prevalent enough that it was the first to be addressed head-on by Kimura (1983) nearly 30 years ago in section 3.6 of his book The Neutral Theory of Molecular Evolution entitled “On some misunderstandings and criticisms” (emphasis is mine):

Since a number of criticisms and comments have been made regarding my neutral theory, often based on misunderstandings, I would like to take this opportunity to discuss some of them. The neutral theory by no means claims that the genes involved are functionless as mistakenly suggested by Zuckerkandl (1978). They may or may not be, but what the neutral theory assumes is that the mutant forms of each gene participating in molecular evolution are selectively nearly equivalent, that is, they can do the job equally well in terms of survival and reproduction of the individual. (p. 50)

As pointed out by Kimura and Ohta (1977), functional constraints are consistent with neutral substitutions within a class of mutants. For example, if a group of amino acids are constrained to be hydrophilic, there can be random changes within the codons producing such amino acids…There is, of course, negative selection against hydrophobic mutants in this region, but, as mentioned before, negative selection does not contradict the neutral theory.  (p. 53)

It is understandable how this misconception arises, because in the limit of zero functional constraint (e.g. in a non-functional pseudogene), all alleles become effectively equivalent to one another and are therefore selectively neutral. However, this does not mean that an unconstrained sequence is Neutral (unless we redefine the meaning of Neutrality, see below), because a sequence itself cannot be Neutral, only variants of a sequence can be Neutral with respect to each other.

It is crucial in this context to understand that the Neutral Theory accommodates all levels of selective constraint, and sequences under selective constraint can evolve Neutrally (see formal statement of this in Equation 5.1 of Kimura 1983). This point is often lost on many people. Until you get this, you don’t understand the Neutral Theory. A simple example shows how this is true. Consider a single codon in a protein coding region that codes for a degenerate amino acid. Deletion of the third codon position would creat a frameshift, and thus a third position “silent” site is indeed functional. However, alternative codons for this amino acid are functionally equivalent and evolve (close to) neutrally. The fact that these alternative alleles evolve neutrally has to do with their equivalence of function, not the degree of their functional constraint.

~~~~

To demonstrate the The Neutral Sequence Fallacy, I’d like to point out a few clear examples of this misconception in action.  The majority of transgressions in this area come from the genomics community where people may not have been formally trained in evolution, but I am sad to say that an increasing number of evolutionary biologists are also falling victim to The Neutral Sequence Fallacy these days. My reckoning is that the The Neutral Sequence Fallacy gained traction again in the post-genomic era around the time of the mouse genome paper by Waterston et al. (2002). In this widely-read paper, putatively unconstrained ancestral repeats were referred to (incorrectly) as “neutrally evolving DNA”, and used to estimate the fraction of the human genome under selective constraint. This analysis culminated with the following question: “How can we cleanly separate neutral and selected sequences?”. Under the Neutral Theory, this question makes no sense. First, sequences cannot be neutral; and second the framework used to detect functional constraints by comparative genomics assumes Neutral evolution of both classes of sites (unconstrained and constrained) – i.e. most changes between species are driven by Genetic Drift not Positive Selection. The proper formulation of this question should have been: “How can we cleanly separate unconstrained and constrained sequences?”.

Here is another clear example of the Neutral Sequence Fallacy in action from Lunter et al. (2006):

Figure 5 from Lunter et al. (2006). Notice how in the top panel, regions of the genome are contrasted as being “Neutral” vs. “Functional”. Here the term “Neutral” is being used incorrectly to mean selectively unconstrained. The bottom panel shows how indels are suppressed in Functional regions leading to intergap segments.

Here are a couple of more examples of the Neutral Sequence Fallacy in action, right in the title of fairly high-profile comparative genomics papers:

Title from Enlistki et al (2003). Notice that the functional class of “Regulatory DNA” is incorrectly contrasted as being the complement of nonfunctional “Neutral Sites”. In fact, both classes of sites are assumed to evolve neutrally in the authors’ model.

Title from Chin et al (2005). As above, notice how the concept of “Functionally conserved” is incorrectly stated to be the opposite of “Neutral sequence” and both classes of sites are assumed to evolve neutrally in the authors’ model.

I don’t mean to single these papers out, they just happen to represent very clear examples of the Neutral Sequence Fallacy in action. In fact, the Lunter et al. (2006) paper is one of my all time favorites, but it bugs the hell out of me when I have to unpick student’s misconceptions after they read it. Frustratingly, the list of papers repeating the Neutral Sequence Fallacy is long and growing. I have recently started to collect them as a citeulike library to provide examples for students to understand how not to make this common mistake. (If anyone else would like to contribute to this effort, please let me know — there is much work to be done to reverse this trend.)

~~~~

So what’s the big deal here?  Some would argue that these authors actually know what they are talking about, but they just happen to be using the wrong terminology. I wish that this were the case, but very often it is not. In many papers that I read or review that perpetrate the Neutral Sequence Fallacy, I usually find further examples of seriously flawed evolutionary reasoning, suggesting that they actually do not have a deep understanding of the issues at hand. In fact, evidence of the Neutral Sequence Fallacy is usually a clear hallmark in a paper that the authors are most likely practicing population genetics or molecular evolution without a license. This leads to a Neutral Sequence Fallacy of the 1st Kind: where authors do not understand the difference between the concepts functional constraint and selective neutrality. The problems for the Neutral Theory caused by violations of the 1st Kind are deep and clear. Because the Neutral Theory is not fully understood, it is possible to construct a straw-man version of the null hypothesis of Neutrality that can easily be “rejected” simply by finding evidence of selective constraint. Furthermore, because selectively unconstrained sequences are asserted (incorrectly) to be “Neutral” without actually evaluating their mode of evolution, this conceptual error undermines the entire value of the Neutral Theory as a null hypothesis testing framework.

But some authors really do know the difference between these ideas, and just happen to be using the term “Neutral” as shorthand for the term “Unconstrained.” Increasingly, I see some of my respected peers making this mistake in print who are card-carrying molecular evolutionists and do know their stuff. In these cases what is happening is a Neutral Sequence Fallacy of the 2nd Kind: understanding the difference between functional constraint and selective neutrality, but using lazy terminology that confuses these ideas in print. This is most often found in the context of studies on noncoding DNA where, in the absence of the genetic code to conveniently constrain terminology, people use terms like “neutral standard” or “neutral region” or “neutral sites” or “neutral proxy” in place of  “putatively unconstrained”. While the meaning of violations of the 2nd Kind can be overlooked and parsed correctly by experts in molecular evolution (I hope), this sloppy language causes substantial confusion about the Neutral Theory by students or non-evolutionary biologists who are new to the field, and leads to whole swathes of subsequent violations of the 1st Kind. Moreover, defining sequences as Neutral serves those with an Adaptationist agenda: since a control region is defined as being Neutral, all mutations that occur in that region must therefore be neutral as well, and thus any potential complications of the non-neutrality of mutations in one’s control region are conveniently swept under the carpet. Violations of the 2nd Kind are often quite insidious since they are generally perpetrated by people with some authority in evolutionary biology, often who are unaware of their misuse of terminology and who will vigorously deny that they are using terms which perpetuate a classical misconception laid to rest by Kimura 30 years ago.

~~~~

Which brings us to the most recent incarnation of the Neutral Sequence Fallacy in the context of the ENCODE project. In a companion post explaining the main findings of the ENCODE Project, Ewan Birney describes how the ENCODE Project reinforced recent findings that many biochemical events operate on the genome that are highly reproducible, but have no known function. In describing these event, Birney states:

I really hate the phrase “biological noise” in this context. I would argue that “biologically neutral” is the better term, expressing that there are totally reproducible, cell-type-specific biochemical events that natural selection does not care about. This is similar to the neutral theory of amino acid evolution, which suggests that most amino acid changes are not selected either for or against…Whichever term you use, we can agree that some of these events are “neutral” and are not relevant for evolution.

Under the standard view of the Neutral Theory, Birney misuses the term “Neutral” here to mean lack of functional constraint, repeating the classical form of the Neutral Sequence Fallacy. Because of this, I argue that Birney’s proposed terminology be rejected, since it will perpetuate a classic misconception in Biology. Instead, I propose the term “biologically inert”.

But wait a minute, you say, this is actually a transgression of the 2nd Kind. Really what is going on here is a matter of semantics. Birney knows the difference between functional constraint and selective neutrality. He is just formalizing the creeping misuse of the term Neutral to mean “Nonfunctional” that has been happening over the last decade.  If so, then I argue he is proposing to assign to the term Neutral the primary misconception of the Neutral Theory previously debunked by Kimura. This is a very dangerous proposal, since it will lead to further confusion in genomics arising from the “overloading” of the term Neutral (Kimura’s meaning: selectively equivalent; Birney’s meaning: no functional constraint). This muddle will subsequently prevent most scientists from properly understanding the Neutral Theory, and lead to many further examples of the Neutral Sequence Fallacy of both Kinds.

In my view, semantic switches like this are dangerous in Science, since they massively hinder communication and, therefore, progress. Semantic switches also lead to a distortion of understanding about key concepts in science. A famous case in point is Watson’s semantic switch of Crick’s term “Central Dogma” that corrupted Crick’s beautifully crafted original concept into the watered down textbook misinterpretation that is most often repeated: “DNA makes RNA make protein” (See Larry Moran’s blog for more on this).  Some may say this is the great thing about language, the same word can mean different things to different people. This view is best characterized in the immortal words of Humpty-Dumpty in Lewis Carroll’s Through the Looking Glass:

Others, including myself, disagree and prefer to have fixed definitions for scientific terms.

In a second recent case of the Neutral Sequence Fallacy creeping into discussions in the context of ENCODE, Michael Eisen proposes that we develop a “A neutral theory of molecular function” to interpret the meaning of these reproducible biochemical events that have no known function. Inspired by the introduction of a new null hypothesis in evolutionary biology ushered in by the Neutral Theory, Eisen calls for a new “neutral null hypothesis” that requires the molecular functions to be proven, not assumed. I laud any attempt to promote the use of null models for hypothesis testing in molecular biology, and whole-heartedly agree with Eisen’s main message about the need for a null model for molecular function.

But I disagree with Eisen’s proposal for a “neutral null hypothesis”, which from my reading of his piece, directly couples the null hypothesis for function with the null hypothesis for sequence evolution. By synonymizing the Ho of the functional model with the Ho of the evolutionary model, regions of the genome that would fail to reject the null functional model (i.e. have no functional constraint) will then be conflated with “being Neutral” (incorrect) or evolving neutrally (potentially correct), whereas those regions that reject the null functional model will be immediately considered as evolving non-neutrally (which may not always be the case since functional regions can evolve neutrally). While I assume this is not what is intended by Eisen, this is almost inevitably the outcome of suggesting a “neutral null hypothesis” in the context of biomolecular sequences. A “neutral null hypothesis for molecular function” makes it all to easy to merge the concepts of functional constraint and selective neutrality, which will inevitably lead many to the Neutral Sequence Fallacy. As Kimura does, Eisen should formally decouple the concept of functional constraint on a sequence from the mode of evolution by which that sequence evolves. Eisen should instead be promoting a “A null model of molecular function” that cleanly separates the concepts of function and evolution (an example of such a null model is embodied in Sean Eddy’s Random Genome Project). If not, I fear this conflation of concepts, like Birney’s semantic switch, will lead to more examples of the Neutral Sequence Fallacy of both Kinds.

~~~~

The Neutral Sequence Fallacy shares many sociological similarities with the chronic misuse and misconceptions about the concept of Homology. As discussed by Marabotti and Facchiano in their article “When it comes to homology, bad habits die hard“, there was a peak of misuse of the term Homology in the mid-1980s, which lead to backlash of many publications demanding more rigorous use of the term Homology. Despite this backlash and the best efforts of many scientists to stem the tide of misuse of Homology, ~43% of abstracts surveyed in 2007 use Homology incorrectly, down from 51% in 1986 before the assault on its misuse began. As anyone teaching the concept knows, unpicking misconceptions about Homology vs. Similarity is crucial for getting students to understand evolutionary theory. I argue that the same is true for the distinction between Functional Constraint and Selective Neutrality. When it comes to Functional Constraints on biomolecular sequences, our choice of terminology should be anything but Neutral.

References:

Chin CS, Chuang JH, & Li H (2005). Genome-wide regulatory complexity in yeast promoters: separation of functionally conserved and neutral sequence. Genome research, 15 (2), 205-13 PMID: 15653830

Elnitski L, Hardison RC, Li J, Yang S, Kolbe D, Eswara P, O’Connor MJ, Schwartz S, Miller W, & Chiaromonte F (2003). Distinguishing regulatory DNA from neutral sites. Genome research, 13 (1), 64-72 PMID: 12529307

Lunter G, Ponting CP, & Hein J (2006). Genome-wide identification of human functional DNA using a neutral indel model. PLoS computational biology, 2 (1) PMID: 16410828

Marabotti A, & Facchiano A (2009). When it comes to homology, bad habits die hard. Trends in biochemical sciences, 34 (3), 98-9 PMID: 19181528

Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE, Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P, Cawley S, Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C, Collins FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly M, David R, Davies J, Delehaunty KD, Deri J, Dermitzakis ET, Dewey C, Dickens NJ, Diekhans M, Dodge S, Dubchak I, Dunn DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyras E, Felsenfeld A, Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey TS, Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt L, Grafham D, Graves TA, Green ED, Gregory S, Guigó R, Guyer M, Hardison RC, Haussler D, Hayashizaki Y, Hillier LW, Hinrichs A, Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I, Jaffe DB, Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK, Karolchik D, Kasprzyk A, Kawai J, Keibler E, Kells C, Kent WJ, Kirby A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas EJ, Kulp D, Landers T, Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S, Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH, McCarthy M, McCombie WR, McLaren S, McLay K, McPherson JD, Meldrim J, Meredith B, Mesirov JP, Miller W, Miner TL, Mongin E, Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O’Connor MJ, Okazaki Y, Oliver K, Overton-Larty E, Pachter L, Parra G, Pepin KH, Peterson J, Pevzner P, Plumb R, Pohl CS, Poliakov A, Ponce TC, Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM, Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J, Schwartz MS, Schwartz S, Scott C, Seaman S, Searle S, Sharpe T, Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G, Smit A, Smith DR, Spencer B, Stabenau A, Stange-Thomann N, Sugnet C, Suyama M, Tesler G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C, Ureta-Vidal A, Vinson JP, Von Niederhausern AC, Wade CM, Wall M, Weber RJ, Weiss RB, Wendl MC, West AP, Wetterstrand K, Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson RK, Winter E, Worley KC, Wyman D, Yang S, Yang SP, Zdobnov EM, Zody MC, & Lander ES (2002). Initial sequencing and comparative analysis of the mouse genome. Nature, 420 (6915), 520-62 PMID: 12466850

Credits:

Thanks to Chip Aquadro for originally pointing out to me when I perpetrated the Neutral Sequence Fallacy (of the 1st Kind!) during a journal club as an undergraduate in his lab. I can distinctly recall hot, embarrassment of the moment while being schooled in this important issue by a master. Thanks also to Alan Moses, who was the first of many people I converted to the light on this issue, and who has encouraged me since to write this up for a wider audience. Thanks also to Douda Bensasson for putting up with me ranting about this issue for years, and helpful comments on this post.

Related Posts:

Will the Democratization of Sequencing Undermine Openness in Genomics?

It is no secret, nor is it an accident, that the success of genome biology over the last two decades owes itself in large part to the Open Science ideals and practices that underpinned the Human Genome Project. From the development of the Bermuda principles in 1996 to the Ft. Lauderdale agreement in 2003, leaders in the genomics community fought for rapid, pre-publication data release policies that have (for the most part) protected the interests of genome sequencing centers and the research community alike.

As a consequence, progress in genomic data acquisition and analysis has been incredibly fast, leading to major basic and medical breakthroughs, thousands of publications, and ultimately to new technologies that now permit extremely high-throughput DNA sequencing. These new sequencing technologies now give individual groups sequencing capabilities that were previously only acheivable by large sequencing centers. This development makes it timely to ask: how do the data release policies for primary genome sequences apply in the era of next-generation sequencing (NGS)?

My reading of the the history of genome sequence release policies condenses the key issues as follows:

  • The Bermuda Principles say that assemblies of primary genomic sequences of human and other organims should be made within 24 hrs of their production
  • The Ft. Lauderdale Agreement says that whole genome shotgun reads should be deposited in public repositories within one week of generation. (This agreement was also encouraged to be applied to other types of data from “community resource projects” – defined as research project specifically devised and implemented to create a set of data, reagents or other material whose primary utility will be as a resource for the broad scientific community.)

Thus, the agreed standard in the genomics field is that raw sequence data from the primary genomic sequence of organisms should be made available within a week of generation. In my view this also applies to so-called “resequencing” efforts (like the 1000 Genomes Project), since genomic data from a new strain or individual is actually a new primary genome sequence.

The key question concerning genomic data release policies in the NGS era, then, is do these data release policies apply only to sequencing centers or to any group producing primary genomic data? Now that you are a sequencing center, are you also bound by the obligations that sequencing centers have followed for a decade or more? This is an important issue to discuss for it’s own sake in order to promote Open Science, but also for the conundrums it throws up about data release policies in genomics. For example, if individual groups who are sequencing genomes are not bound by the same data release policies as sequencing centers, then a group at e.g. Sanger or Baylor working on a genome is actually now put at a competetive disadvantage in the NGS era because they would be forced to release their data.

I argue that if the wider research community does not abide by the current practices of early data release in genomics, the democratization of sequencing will lead to the slow death of openness in genomics. We could very well see a regression to the mean behavior of data hording (I sometimes call this “data mine, mine, mining”) that is sadly characteristic of most of biological sciences. In turn this could decelerate progress in genomics, leading to a backlog of terabytes of un(der)analyzed data rotting on disks around the world. Are you prepared to standby, do nothing and bear witness to this bleak future? ; )

While many individual groups collecting primary genomic sequence data may hesitate to embrace the idea of pre-publication data release, it should be noted that there is also a standard procedure in place for protecting the interests of the data producer to have first chance to publish (or co-publish) large-scale analysis of the data, while permitting the wider research community to have early access. The Ft. Lauderdale agreeement recognized that:

…very early data release model could potentially jeopardize the standard scientific practice that the investigators who generate primary data should have both the right and responsibility to publish the work in a peer-reviewed journal. Therefore, NHGRI agreed to the inclusion of a statement on the sequence trace data permitting the scientific community to use these unpublished data for all purposes, with the sole exception of publication of the results of a complete genome sequence assembly or other large-scale analyses in advance of the sequence producer’s initial publication.

This type of data producer protection proviso has being taken up by some community-led efforts to release large amounts of primary sequence data prior to publiction, as laudably done by the Drosophila Population Genomics Project (Thanks Chuck!)

While the Ft. Lauderdale agreement in principle tries to balance the interests of the data producers and consumers, it is not without failings. As Mike Eisen points out on his blog:

In practice [the Ft. Lauderdale privoso] has also given data producers the power to create enormous consortia to analyze data they produce, effectively giving them disproportionate credit for the work of large communities. It’s a horrible policy that has significantly squelched the development of a robust genome analysis community that is independent of the big sequencing centers.

Eisen rejects the Ft. Lauderdale agreement in favor of a new policy he entitles The Batavia Open Genomic Data Licence.  The Batavia License does not require an embargo period or the need to inform data producers of how they intend to use the data, as is expected under the Ft. Lauderdale agreement, but it requires that groups using the data publish in an open access journal. Therefore the Batavia License is not truly open either, and I fear that it imposes unnecessary restrictions that will prevent its widespread uptake. The only truly Open Science policy for data release is a Creative Commons (CC-BY or CC-Zero) style license that has no restrictions other than attribution, a precedent that was established last year for the E. coli TY-2482 genome sequence (BGI you rock!).

A CC-style license will likely be too liberal for most labs generating their own data, and thus I argue we may be better off pushing for a individual groups to use a Ft. Lauderdale style agreement to encourage the (admittedly less than optimal) status quo to be taken up by the wider community. Another option is for researchers to release their data early via “data publications” such as those being developed by journals such as GigaScience and F1000 Reports.

Whatever the mechanism, I join with Eisen in calling for wider participation for the research to community to release their primary genomic sequence data. Indeed, it would be a truly sad twist of fate if the wider research community does not follow the genomic data release policies in the post-NGS era that were put in place in the pre-NGS era in order to protect their interests. I for one will do my best in the coming years to reciprocate the generosity that has made Drosophila genomics community so great (in the long tradition of openness dating back to the Morgan school), by releasing any primary sequence data produced by my lab prior to publication. Watch this space.